Product
Dexamethasone
Aliases
0.05mg/kg Dexamethasone, 0,1mg/kg Dexamethasone, 0.1mg/kg Dexamethasone, 0,2mg/kg Dexamethasone, Aacidexam (124 other aliases)
Name
Hemady
INN Name
Dexamethasone
FDA Approved
Yes
580 clinical trials
3 organizations
531 indications
2 documents
Indication
Multiple MyelomaIndication
Eye InflammationIndication
PainIndication
PostoperativeIndication
CataractIndication
LeukemiaIndication
HyperuricemiaIndication
Acute Myeloid LeukemiaIndication
Immune Thrombocytopenia (ITP)Indication
Multiple myelomaIndication
Plasma CellIndication
multiple myelomaIndication
Diabetic Macular EdemaIndication
Prostate CancerIndication
Fabry's DiseaseIndication
RefractoryIndication
Non-Hodgkin lymphomaIndication
Diffuse Large B-cell LymphomaIndication
Ataxia TelangiectasiaIndication
Acute Lymphoblastic LeukemiaIndication
Haematological MalignancyIndication
Non-Hodgkin LymphomaIndication
Myelodysplastic SyndromeIndication
Peripheral T Cell LymphomaIndication
lymphomaIndication
Non-Hodgkin'sIndication
Multiple SclerosisIndication
Primary Progressive Multiple SclerosisIndication
B-Cell Non-Hodgkin LymphomaIndication
Esophageal squamous cell carcinomaIndication
Chemotherapy-induced Nausea and VomitingIndication
Large B-cell LymphomaIndication
Acute LymphoblasticIndication
Relapsed Refractory Multiple MyelomaIndication
AnaphylaxisIndication
hematologic malignanciesIndication
Macular EdemaIndication
Renal ImpairmentIndication
Relapsed/Refractory Multiple MyelomaIndication
Metastatic Colorectal CancerIndication
Higher-Risk Myelodysplastic SyndromeIndication
MDSIndication
COVID-19Indication
Non-HodgkinIndication
COVID-19 PneumoniaIndication
RRMMIndication
VitrectomyIndication
Epiretinal MembraneIndication
Hematological MalignancyIndication
Relapsed/RefractoryIndication
Urinary Tract Infections in ChildrenIndication
DexamethasoneIndication
NephrosclerosisIndication
PyelonephritisIndication
HypertensionIndication
Chronic Kidney DiseaseIndication
Urinary Tract InfectionIndication
Diffuse Large B-Cell LymphomaIndication
Non-squamous non-small cell lung cancerIndication
KEAP1 Gene MutationIndication
NRF2 gene mutationIndication
NFE2L2 Gene MutationIndication
DermatitisIndication
Cataract Surgery ComplicationsIndication
Hematologic MalignancyIndication
Refractory Hematologic MalignancyIndication
Non-Small-Cell Lung CarcinomaIndication
Plasma cell disordersIndication
Hodgkin lymphomaIndication
Solid TumorIndication
HealthyIndication
Non-Hodgkin's LymphomaIndication
acute myeloid leukemiaIndication
Inflammatory ResponseIndication
NauseaIndication
Urinary incontinenceIndication
Sexual BehaviorIndication
BronchiolitisIndication
LeiomyomaIndication
Hemophagocytic LymphohistiocytosisIndication
Autologous Stem Cell TransplantIndication
Postoperative Sore ThroatIndication
Relapsed Multiple MyelomaIndication
mantle cell lymphomaIndication
Foot Injuries and DisordersIndication
Ankle Injuries and DisordersIndication
Adult T Acute Lymphoblastic LeukemiaIndication
Stage II Adult Lymphoblastic LymphomaIndication
Childhood Lymphoblastic LymphomaIndication
Stage IV Adult Lymphoblastic LymphomaIndication
Childhood Acute Lymphoblastic LeukemiaIndication
Post-operative Nausea and VomitingIndication
Sleeve GastrectomyIndication
AmyloidosisIndication
Osteoarthritis, KneeIndication
Arthroplasty ComplicationsIndication
Postoperative PainIndication
Wrist DiseaseIndication
Hand Injuries and DisordersIndication
SciaticaIndication
Breast CancerIndication
ER-positive Breast CancerIndication
Estrogen Receptor Gene MutationIndication
Colorectal DisordersIndication
Regional Anesthesia MorbidityIndication
AnalgesicIndication
Local Anesthetic ComplicationIndication
Colorectal CancerIndication
Crohn's DiseaseIndication
Diverticular DiseaseIndication
B-Cell Lymphoblastic LymphomaIndication
Stage I B Lymphoblastic LymphomaIndication
Stage II B Lymphoblastic LymphomaIndication
Childhood B Lymphoblastic LymphomaIndication
Down syndromeIndication
TuberculosisIndication
Tuberculous MeningitisIndication
Drug-Induced Liver InjuryIndication
HIVIndication
Philadelphia Chromosome PositiveIndication
Oral Lichen PlanusIndication
Mucous Membrane PemphigoidIndication
Pemphigus vulgarisIndication
Chronic Graft-versus-host diseaseIndication
Multiple Myeloma in RelapseIndication
CancerIndication
GammopathyIndication
MonoclonalIndication
ParaproteinemiaIndication
Protein Metabolism DisordersIndication
Hematologic DiseaseIndication
Corneal DiseaseIndication
AL AmyloidosisIndication
Primary Plasma Cell LeukemiaIndication
Extramedullary PlasmacytomaIndication
TonsillectomyIndication
SurgeryIndication
Periodontal DiseaseIndication
EdemaIndication
Patient SatisfactionIndication
periodontitisIndication
AsthmaIndication
Spinal FusionIndication
Spinal DiseasesIndication
Spinal StenosisIndication
Erector Spinae Plane BlockIndication
Ankle DiseaseIndication
Ankle InjuriesIndication
Foot InjuryIndication
Foot DiseasesIndication
MigraineIndication
Orthopedic surgeryIndication
B Lymphoblastic LymphomaIndication
Leptomeningeal MetastasesIndication
Acute Undifferentiated LeukemiaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Sickle Cell DiseaseIndication
Sickle Cell AnemiaIndication
Respiratory DisorderIndication
FunctionalIndication
ImpairedIndication
CholangiocarcinomaIndication
Primary Central Nervous System LymphomaIndication
Immune ThrombocytopeniaIndication
T Lymphoblastic LymphomaIndication
Malignant Brain NeoplasmIndication
Brain MetastasesIndication
Recurrent Malignant Brain NeoplasmIndication
Lymphoblastic LymphomaIndication
Mixed Phenotype Acute LeukemiaIndication
Osteoarthritis of the KneeIndication
Testicular LeukemiaIndication
MesotheliomaIndication
Lassa feverIndication
Anaplastic Large Cell LymphomaIndication
ALK-positiveIndication
Childhood Anaplastic Large Cell LymphomaIndication
Diabetic RetinopathyIndication
Metastatic Appendiceal AdenocarcinomaIndication
Intraperitoneal PaclitaxelIndication
lung cancerIndication
Lung DiseasesIndication
Waldenstrom MacroglobulinemiaIndication
Metastatic Malignant Solid NeoplasmIndication
PediatricIndication
Interstitial Lung DiseaseIndication
Hospital-Acquired PneumoniaIndication
headacheIndication
occipital nerve blockIndication
Recurrent Acute LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
BCR-ABL1-positiveIndication
Hairy Cell LeukemiaIndication
Recurrent Hematologic MalignancyIndication
Hodgkin LymphomaIndication
Recurrent T Acute Lymphoblastic LeukemiaIndication
Refractory Acute LeukemiaIndication
Hodgkin's LymphomaIndication
Systemic MastocytosisIndication
Acute Heart FailureIndication
Stomach CancerIndication
Systemic amyloidosisIndication
Pain ManagementIndication
Acute Respiratory Distress SyndromeIndication
Respiratory Distress SyndromeIndication
AcuteIndication
Primary AmyloidosisIndication
Recurrent Primary AmyloidosisIndication
MammaplastyIndication
Osteoarthritis of the hipIndication
Avascular Necrosis of HipIndication
Polycystic Ovary SyndromeIndication
ObesityIndication
HyperandrogenismIndication
Adult Lymphoblastic LymphomaIndication
Leukemia, BurkittIndication
Burkitt LymphomaIndication
Recurrent High Grade B-Cell LymphomaIndication
Burkitt LeukemiaIndication
Burkitt lymphomaIndication
Acute Promyelocytic LeukemiaIndication
Sacroiliac Joint DysfunctionIndication
Sacroiliac SpondylosisIndication
RadiopharmaceuticalIndication
CholesterolIndication
Intrahepatic CholangiocarcinomaIndication
Bile Duct CancerIndication
Bile Duct NeoplasmsIndication
Hepatocellular CarcinomaIndication
Relapsed CancerIndication
Coronary Artery DiseaseIndication
Aortic Valve DiseaseIndication
pulpitisIndication
Hand SurgeryIndication
PancreaticoduodenectomyIndication
Hip DysplasiaIndication
Postoperative Nausea and VomitingIndication
Acute Lymphoblastic Leukemia (ALL)Indication
Tonsillar BleedingIndication
MedulloblastomaIndication
EpendymomaIndication
OsteoarthritisIndication
KneeIndication
Solid TumorsIndication
Difficulty swallowingIndication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
Breast Cancer, Stage IVIndication
Stage 0 Breast CancerIndication
Breast Cancer AJCC Stage IAIndication
Stage IIA Breast CancerIndication
Stage IIIA Breast CancerIndication
Stage IIIB Breast CancerIndication
Stage IV Breast Cancer AJCC v8Indication
Oral Lichenoid ReactionIndication
Osteoarthritis, HipIndication
Hip ArthropathyIndication
Knee ReplacementIndication
Genicular Nerve BlockIndication
Opioid UseIndication
Adult Acute Lymphoblastic LeukemiaIndication
Chronic Hip PainIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Crohn's diseaseIndication
Perioperative OptimizationIndication
TumorIndication
RhabdomyolysisIndication
Gynecologic CancerIndication
Spinal AnesthesiaIndication
Plasma Cell LeukemiaIndication
PlasmacytomaIndication
Abdominal Aortic AneurysmIndication
Endovascular Aneurysm RepairIndication
Postimplantation SyndromeIndication
InflammationIndication
MorphineIndication
AnalgesicsIndication
OpioidIndication
Peripheral Nervous System AgentsIndication
Granulocyte DonationIndication
ETP-ALLIndication
ToxoplasmosisIndication
CerebralIndication
ScoliosisIndication
Hand InjuriesIndication
Wrist InjuriesIndication
Hand DiseaseIndication
RelapseIndication
AgingIndication
ComorbidityIndication
AnaemiaIndication
DysphoniaIndication
Waldenström macroglobulinemiaIndication
Radiation-Induced Intestinal InjuryIndication
Philadelphia Chromosome NegativeIndication
High-Grade B-Cell LymphomaIndication
NOSIndication
Neonatal Respiratory Distress SyndromeIndication
premature birthIndication
Mantle Cell LymphomaIndication
Severe Acute Respiratory Syndrome (SARS)Indication
Virus DiseasesIndication
Coronavirus InfectionsIndication
Nidovirales InfectionsIndication
RNA Virus InfectionsIndication
Respiratory Tract InfectionsIndication
Respiratory Tract DiseaseIndication
Malignant NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Newly DiagnosedIndication
High-riskIndication
Minimal residual diseaseIndication
Acute bilineal leukemiaIndication
Acute Biphenotypic LeukemiaIndication
Acute Leukemia of Ambiguous LineageIndication
B-myeloidIndication
T-Cell MyeloidIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Acute PericarditisIndication
Cardiac ArrestIndication
Post-Cardiac Arrest SyndromeIndication
PurpuraIndication
ThrombocytopeniaIndication
IdiopathicIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Myelodysplastic SyndromesIndication
de NovoIndication
SecondaryIndication
Previously TreatedIndication
Therapy-Related Myelodysplastic SyndromeIndication
Hemophagocytic LymphohistiocytosesIndication
Atrioventricular BlockIndication
Fetal atrioventricular blockIndication
Acute lymphoblastic leukemiaIndication
Post Procedural InfectionIndication
ChildhoodIndication
t(11;14)Indication
Obstructive Sleep ApneaIndication
Natural Killer/T-Cell LymphomaIndication
Nasal and Nasal-TypeIndication
T-lymphoblastic lymphomaIndication
Myeloma-associated amyloidosisIndication
Hip FracturesIndication
Smoldering Plasma Cell MyelomaIndication
Foot DeformitiesIndication
Cerebral PalsyIndication
PneumoniaIndication
Bone metastasesIndication
Cervical CancerIndication
Nasopharyngeal CancerIndication
Radiation-Induced Nausea and VomitingIndication
AntiemeticIndication
Cervical FusionIndication
Trigger FingerIndication
Colorectal Cancer MetastaticIndication
Mature B-cell Non-Hodgkin LymphomaIndication
Lumbar Spinal StenosisIndication
Intervertebral Disc DegenerationIndication
Disc DiseaseIndication
Shoulder ArthropathyIndication
B-cell Non-Hodgkin LymphomaIndication
BCR-ABL1-likeIndication
Acute lymphoblastic leukemia, adult typeIndication
Adult L1 Acute Lymphoblastic LeukemiaIndication
Shoulder ArthroplastyIndication
Plantar FasciitisIndication
Shoulder PainIndication
Graves diseaseIndication
Hashimoto ThyroiditisIndication
NK-Cell LymphomaIndication
NK Cell LeukemiaIndication
Opsoclonus-Myoclonus SyndromeIndication
NeuroblastomaIndication
neuritisIndication
Radiofrequency AblationIndication
Adolescent Idiopathic ScoliosisIndication
Respiratory Distress Syndrome of NewbornIndication
TrismusIndication
Smoldering MyelomaIndication
Smoldering Multiple MyelomaIndication
Hearing impairmentIndication
SuddenIndication
OtotoxicIndication
Ocular InflammationIndication
Ocular ProsthesesIndication
Pre B-Cell Acute Lymphoblastic LeukaemiaIndication
BPDCNIndication
B-cellIndication
T cellIndication
Dry Eye SyndromeIndication
Post-Operative Nausea and VomitingIndication
Carpal TunnelIndication
DexmedetomidineIndication
OzoneIndication
T-cell Acute Lymphoblastic LeukemiaIndication
T-cell LymphomaIndication
Noise-InducedIndication
Meniere's diseaseIndication
FractureIndication
BoneIndication
ClosedIndication
Distal Radius FractureIndication
lumbar spinal stenosisIndication
POEMS syndromeIndication
Stress-Related DisorderIndication
NutritionIndication
MetabolismIndication
HPV-Related Squamous Cell CarcinomaIndication
HNSCCIndication
SepsisIndication
Advanced Malignant NeoplasmIndication
FatigueIndication
Metastatic Malignant NeoplasmIndication
Recurrent Malignant NeoplasmIndication
CryptorchismIndication
rheumatic feverIndication
Sydenham's ChoreaIndication
Knee ArthropathyIndication
Peripheral T-Cell LymphomaIndication
MultipleIndication
Stomach AdenocarcinomaIndication
CarcinomatosisIndication
Sore ThroatIndication
Supraglottic Airway DevicesIndication
ACL InjuryIndication
insomniaIndication
Surgical FieldIndication
Wrist FractureIndication
Acute Lymphoblastic LymphomaIndication
DyspneaIndication
TonsillitisIndication
Hemophagocytic SyndromeIndication
Low blood pressureIndication
Low-grade gliomaIndication
Brain GliomaIndication
MeningiomaIndication
GlioblastomaIndication
Malignant GliomaIndication
Hypersensitivity ReactionsIndication
17p LossIndication
Pediatric CancerIndication
AnesthesiaIndication
LocalIndication
Herniated DiscIndication
SpondylolisthesisIndication
Lumbar Spine InstabilityIndication
Calcific TendinitisIndication
Multiple Myeloma at First RelapseIndication
Inguinal HerniaIndication
RadiculopathyIndication
Lumbosacral RegionIndication
Back Pain With RadiationIndication
Low Back PainIndication
Stem Cell TransplantationIndication
DS Stage I Plasma Cell MyelomaIndication
Stage III Plasma Cell MyelomaIndication
Dengue feverIndication
Ph-Like Acute Lymphoblastic LeukemiaIndication
AdultIndication
Immune Thrombocytopenia PurpuraIndication
Subarachnoid Hemorrhage (Aneurysmal)Indication
Total Knee Arthroplasty StiffnessIndication
Kidney FailureIndication
Chronic PainIndication
Follicular LymphomaIndication
Marginal Zone B-Cell LymphomaIndication
MALT lymphomaIndication
Small LymphocyticIndication
Angioimmunoblastic T-cell LymphomaIndication
Rebound PainIndication
Intercoastal Nerve BlockIndication
Thoracoscopic SurgeryIndication
Wound InfectionIndication
Retinopathy of PrematurityIndication
Primary AldosteronismIndication
Respiratory FailureIndication
Anterior Cruciate Ligament (ACL) InjuryIndication
Modified Radical MastectomyIndication
SARSIndication
ViralIndication
PulpitisIndication
Pseudophakic Bullous KeratopathyIndication
Fuchs' Endothelial DystrophyIndication
Intraocular PressureIndication
CCND1 TranslocationIndication
venetoclaxIndication
CroupIndication
Community-acquired PneumoniaIndication
InfluenzaIndication
NSCLCIndication
Arthritis KneeClinical trial
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)Status: Active (not recruiting), Estimated PCD: 2018-11-23
Clinical trial
A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Ophthalmic Suspension in the Treatment of Inflammation and Pain Following Cataract SurgeryStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental StudyStatus: Recruiting, Estimated PCD: 2026-09-21
Clinical trial
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2019-10-07
Clinical trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab RetreatmentStatus: Terminated, Estimated PCD: 2022-10-24
Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-02-25
Clinical trial
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)Status: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-09-29
Clinical trial
A Phase I Randomized, Double-blind, Placebo-controlled, Dose-increasing Single Dose Study Evaluating the Safety, Tolerability，Pharmacokinetics and Pharmacodynamics Analysis of Pegloticase in Subjects With Asymptomatic HyperuricemiaStatus: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Phase II, Randomized (1:1) Open Label Study to Assess the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone Compared to Dexamethasone, as First-line Treatment in Adult Patients With Newly Diagnosed Immune ThrombocytopeniaStatus: Completed, Estimated PCD: 2023-09-22
Clinical trial
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory AgentsStatus: Completed, Estimated PCD: 2019-10-18
Clinical trial
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2023-08-09
Clinical trial
Study of EOS884448 Alone, and in Combination With Iberdomide With or Without Dexamethasone, in Participants With Relapsed or Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-11-29
Clinical trial
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)Status: Recruiting, Estimated PCD: 2024-05-23
Clinical trial
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2023-10-02
Clinical trial
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensStatus: Active (not recruiting), Estimated PCD: 2020-08-12
Clinical trial
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-08-28
Clinical trial
A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-11-29
Clinical trial
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)Status: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5Status: Recruiting, Estimated PCD: 2026-02-24
Clinical trial
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE InfusionStatus: Recruiting, Estimated PCD: 2025-10-06
Clinical trial
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)Status: Active (not recruiting), Estimated PCD: 2022-11-30
Clinical trial
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)Status: Recruiting, Estimated PCD: 2026-02-23
Clinical trial
A Phase 2b, Open-label Study of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma (MM), Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory MM, and Selinexor and Pomalidomide Plus Low-dose Dexamethasone (SPd) in Patients With Relapsed Refractory MM.Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122Status: Active (not recruiting), Estimated PCD: 2026-02-25
Clinical trial
An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple MyelomaStatus: Completed, Estimated PCD: 2019-01-31
Clinical trial
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2019-07-14
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-03-19
Clinical trial
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in JapanStatus:
Clinical trial
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)Status: Not yet recruiting, Estimated PCD: 2027-12-06
Clinical trial
Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2016-01-11
Clinical trial
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood CataractStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMMStatus: Not yet recruiting, Estimated PCD: 2025-11-16
Clinical trial
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to LenalidomideStatus: Terminated, Estimated PCD: 2021-02-03
Clinical trial
A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2023-01-24
Clinical trial
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantStatus: Active (not recruiting), Estimated PCD: 2026-04-05
Clinical trial
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)Status: Recruiting, Estimated PCD: 2027-07-06
Clinical trial
MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMAStatus: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-09-07
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06BStatus: Recruiting, Estimated PCD: 2026-11-07
Clinical trial
A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 MinutesStatus: Completed, Estimated PCD: 2020-09-09
Clinical trial
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based ChemotherapyStatus: Recruiting, Estimated PCD: 2028-08-02
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient SettingStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2030-11-11
Clinical trial
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)Status: Recruiting, Estimated PCD: 2030-12-02
Clinical trial
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2027-06-22
Clinical trial
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial TherapyStatus: Active (not recruiting), Estimated PCD: 2025-02-23
Clinical trial
Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALLStatus: Completed, Estimated PCD: 2019-07-17
Clinical trial
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-09-12
Clinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2026-01-12
Clinical trial
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose TherapyStatus: Active (not recruiting), Estimated PCD: 2017-11-21
Clinical trial
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)Status: Recruiting, Estimated PCD: 2032-12-26
Clinical trial
A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-16
Clinical trial
MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-09-11
Clinical trial
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating ElotuzumabStatus: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)Status: Recruiting, Estimated PCD: 2024-10-14
Clinical trial
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-07-14
Clinical trial
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)Status: Not yet recruiting, Estimated PCD: 2027-01-08
Clinical trial
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2032-02-13
Clinical trial
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-12
Clinical trial
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of AnaphylaxisStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory DrugStatus: Withdrawn, Estimated PCD: 2017-06-01
Clinical trial
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)Status: Active (not recruiting), Estimated PCD: 2020-02-18
Clinical trial
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2027-04-01
Clinical trial
A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal FunctionStatus: Terminated, Estimated PCD: 2021-12-22
Clinical trial
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer IndicationsStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITORStatus: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 InfectionStatus: Terminated, Estimated PCD: 2022-04-04
Clinical trial
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-03-09
Clinical trial
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2021-11-29
Clinical trial
An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyStatus: Completed, Estimated PCD: 2021-05-28
Clinical trial
A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic MalignanciesStatus: Completed, Estimated PCD: 2018-12-14
Clinical trial
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2014-06-16
Clinical trial
Evaluation of an Updated Dexamethasone Posterior Segment Drug Delivery System Applicator in Participants With Macular Edema Due to Retinal DiseasesStatus: Completed, Estimated PCD: 2022-02-09
Clinical trial
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple MyelomaStatus: Terminated, Estimated PCD: 2019-09-23
Clinical trial
A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaStatus: Withdrawn, Estimated PCD: 2018-01-01
Clinical trial
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Active (not recruiting), Estimated PCD: 2022-08-12
Clinical trial
A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaStatus: Completed, Estimated PCD: 2016-07-22
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 PneumoniaStatus: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2021-06-11
Clinical trial
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) When Placed Within the Lower Eye Lid Canaliculus or Both the Upper and Lower Canaliculi for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM PatientsStatus: Terminated, Estimated PCD: 2021-06-02
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-05-09
Clinical trial
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological MalignanciesStatus: Completed, Estimated PCD: 2018-12-21
Clinical trial
A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-02-07
Clinical trial
A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 InfectionStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal AntibodyStatus: Completed, Estimated PCD: 2020-10-22
Clinical trial
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or CarfilzomibStatus: Completed, Estimated PCD: 2018-01-19
Clinical trial
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 CarfilzomibStatus: Terminated, Estimated PCD: 2020-09-21
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2014-10-01
Clinical trial
An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaStatus: Completed, Estimated PCD: 2019-12-02
Clinical trial
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-09-11
Clinical trial
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-08-28
Clinical trial
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-01-28
Clinical trial
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-06-24
Clinical trial
A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)Status: Completed, Estimated PCD: 2017-12-15
Clinical trial
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children:A Multi-centre, Double-blind, Randomized, Placebo-controlled, Clinical TrialStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2014-11-10
Clinical trial
A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-31
Clinical trial
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)Status: Completed, Estimated PCD: 2018-01-17
Clinical trial
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)Status: Terminated, Estimated PCD: 2021-11-05
Clinical trial
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple MyelomaStatus: Completed, Estimated PCD: 2019-10-01
Clinical trial
A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib DosingStatus: Completed, Estimated PCD: 2017-06-15
Clinical trial
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second RelapseStatus: Terminated, Estimated PCD: 2022-09-12
Clinical trial
OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryStatus: Recruiting, Estimated PCD: 2023-03-01
Clinical trial
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2023-04-06
Clinical trial
A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.Status: Active (not recruiting), Estimated PCD: 2025-05-24
Clinical trial
Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic DermatitisStatus: Withdrawn, Estimated PCD: 2010-11-01
Clinical trial
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb DaratumumabStatus: Completed, Estimated PCD: 2019-07-26
Clinical trial
(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-10-06
Clinical trial
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2013-03-14
Clinical trial
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6Status: Active (not recruiting), Estimated PCD: 2023-02-28
Clinical trial
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)Status: Completed, Estimated PCD: 2017-11-08
Clinical trial
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic MalignanciesStatus: Withdrawn, Estimated PCD: 2023-07-05
Clinical trial
A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2018-11-22
Clinical trial
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Status: Terminated, Estimated PCD: 2022-01-03
Clinical trial
Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell DiseasesStatus: Withdrawn, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)Status: Completed, Estimated PCD: 2022-01-01
Clinical trial
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)Status: Terminated, Estimated PCD: 2023-06-30
Clinical trial
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2020-09-25
Clinical trial
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)Status: Recruiting, Estimated PCD: 2024-09-16
Clinical trial
A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2020-08-01
Clinical trial
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor TypesStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master ProtocolStatus: Recruiting, Estimated PCD: 2027-12-02
Clinical trial
A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and DexamethasoneStatus: Completed, Estimated PCD: 2021-06-11
Clinical trial
An Open-label, Multi-center, Bilateral, Human Factors Study to Evaluate the Utilization and Safety of a Novel Intracanalicular Insertion Device in Healthy SubjectsStatus: Terminated, Estimated PCD: 2022-11-01
Clinical trial
Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell TransplantationStatus: Completed, Estimated PCD: 2019-01-25
Clinical trial
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesStatus: Terminated, Estimated PCD: 2019-07-25
Clinical trial
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Status: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
Effect of 24 mg Dexamethasone Preoperatively on Surgical Stress, Pain and Recovery in Robotic-assisted Laparoscopic HysterectomyStatus: Completed, Estimated PCD: 2024-02-06
Clinical trial
A Randomized Controlled Trial Comparing Epinephrine and Dexamethasone to Placebo in the Treatment of Infants With BronchiolitisStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Intra-Arterial Dexamethasone for the Alleviation of Pain and Postembolization Syndrome Following Uterine Artery EmbolizationStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic LymphohistiocytosisStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SC BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.Status: Completed, Estimated PCD: 2021-04-01
Clinical trial
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination With Daratumumab, Lenalidomide, and Dexamethasone With or Without Bortezomib as Induction Therapy and Teclistamab in Combination With Daratumumab and Lenalidomide as Maintenance Therapy in Participants With Newly Diagnosed Transplant Eligible Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-15
Clinical trial
Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-07-30
Clinical trial
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)Status: Not yet recruiting, Estimated PCD: 2026-04-20
Clinical trial
Topical Dexamethasone Versus Topical Lidocaine Spray to Reduce Post-intubation Sore Throat in Shoulder Arthroscopic Surgeries: A Comparative StudyStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven MaintenanceStatus: Active (not recruiting), Estimated PCD: 2019-03-01
Clinical trial
Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal SurgeryStatus: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and OncologyStatus: Active (not recruiting), Estimated PCD: 2019-12-01
Clinical trial
Dexamethasone vs. Dexmedetomidine for Popliteal Nerve Block in Pain Management After Pediatric Ankle and Foot SurgeryStatus: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)Status: Active (not recruiting), Estimated PCD: 2020-03-31
Clinical trial
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve GastrectomyStatus: Completed, Estimated PCD: 2019-03-30
Clinical trial
A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Daratumumab Among Transplant Ineligible Older Adults With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2032-01-31
Clinical trial
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
Pre vs. Postoperative Adductor Canal Block for Total Knee Arthroplasty: Prospective Randomized TrialStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Effect of Systematic Dexamethasone on the Duration of Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist SurgeryStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase I Study of Panobinostat in Combination With Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-06-16
Clinical trial
Efficacy of Soluble Dexamethasone by Echo-guided Infiltration Through the Sacrococcygeal Hiatus in Refractory Sciatica: a Prospective Randomised Double-blind Study Versus PlaceboStatus: Completed, Estimated PCD: 2023-03-15
Clinical trial
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 InhibitorsStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)Status: Active (not recruiting), Estimated PCD: 2019-03-31
Clinical trial
A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous MeningitisStatus: Completed, Estimated PCD: 2022-04-30
Clinical trial
Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative DiseasesStatus: Completed, Estimated PCD: 2023-01-06
Clinical trial
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-09-29
Clinical trial
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE 120)Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted TherapiesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-20
Clinical trial
Phase 2 Study of Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Post-operative Course of Dexamethasone to Reduce Tonsillectomy MorbidityStatus: Terminated, Estimated PCD: 2023-07-11
Clinical trial
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAXStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Effect of Submucosal Dexamethasone on Postoperative Pain, Swelling and Trismus After Periodontal Surgery: Randomized Clinical StudyStatus: Completed, Estimated PCD: 2022-04-29
Clinical trial
Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care UnitStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Spine SurgeryStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle SurgeryStatus: Completed, Estimated PCD: 2024-02-23
Clinical trial
Dexamethasone for Acute Migraine. A Randomized Dose-comparison StudyStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel TreatmentStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Post-operative Methylprednisolone Taper Course for Orthopedic SurgeryStatus: , Estimated PCD: 2025-01-01
Clinical trial
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
Phase I/II Clinical Trial of Intrathecal Pemetrexed as First Line Intrathecal Chemotherapy in Patients With Leptomeningeal MetastasisStatus: Active (not recruiting), Estimated PCD: 2023-03-20
Clinical trial
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial TherapyStatus: Recruiting, Estimated PCD: 2031-04-30
Clinical trial
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
Suitability of Periarticular Steroid Injections for Sickle Cell Arthropathy Pain TherapyStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
Effect of the Preoperative Administration of Dexamethasone in the Respiratory Function and Postoperative Symptoms in Women Undergoing Mastectomy for Cancer. Results of a Randomized Clinical Trial.Status: Completed, Estimated PCD: 2015-11-01
Clinical trial
A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic CholangiocarcinomaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Dose-escalating Pilot Study of Orelabrutinib in Combination With Rituximab, Methotrexate and Dexamethasone for Newly-diagnosed Primary Central Nervous System LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IStatus: Active (not recruiting), Estimated PCD: 2022-05-10
Clinical trial
A Multicentre, Randomized, Open-label Study of Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic LymphomaStatus: Withdrawn, Estimated PCD: 2026-09-22
Clinical trial
Comparison of Post Operative Endodontic Pain in Patients With Irreversible Pulpitis Treated With and Without Dexamethasone.Status: Not yet recruiting, Estimated PCD: 2025-01-10
Clinical trial
Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.Status: Active (not recruiting), Estimated PCD: 2025-09-03
Clinical trial
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2020-02-14
Clinical trial
INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaStatus: Not yet recruiting, Estimated PCD: 2034-05-01
Clinical trial
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL AmyloidosisStatus: Not yet recruiting, Estimated PCD: 2030-07-29
Clinical trial
Efficacy of Intravenous Dexamethasone Injection Given 12 and 24 Hours for Pain After Total Knee Arthroplasty: A Prospective Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based TherapyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyStatus: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaStatus: Terminated, Estimated PCD: 2021-12-06
Clinical trial
Safety and Tolerability of Adjunct Dexamethasone in Addition to Standard of Care Antiviral Therapy Compared to Standard of Care Antiviral Therapy Alone for the Treatment of Moderate to Severe Lassa FeverStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-07-13
Clinical trial
Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-InStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSStatus: Completed, Estimated PCD: 2023-10-01
Clinical trial
A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic RetinopathyStatus: Completed, Estimated PCD: 2016-04-01
Clinical trial
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-01-02
Clinical trial
Ultrasound-Guided Erector Spinae Plane Block Versus Intercostal Nerve Block For Postoperative Pain Control in Video-Assisted Thoracoscopic Surgery: A Prospective, Double Blind Randomized Controlled TrialStatus: Completed, Estimated PCD: 2021-06-20
Clinical trial
A Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström MacroglobulinemiaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 1/2 Trial of Selinexor in Combination With Pomalidomide and Dexamethasone ± Carfilzomib for Patients With Proteasome-Inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma (SCOPE)Status: Recruiting, Estimated PCD: 2025-03-04
Clinical trial
Preoperative Radiosurgery for Brain Metastases Planned for Surgical Resection: A Two Arm Pilot StudyStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2019-11-14
Clinical trial
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma PatientsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Status: Recruiting, Estimated PCD: 2028-07-14
Clinical trial
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease: A 2x2 Factorial Randomized Phase II Trial Testing N-Acetyl Cysteine and DexamethasoneStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Clinical trial
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase III, Double-blind, Placebo-controlled, Randomized TrialStatus: Not yet recruiting, Estimated PCD: 2026-03-14
Clinical trial
A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBLStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Treatment of Headache With Occipital Nerve Blocks: Comparison Trial of Anesthetic With or Without DexamethasoneStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-05-05
Clinical trial
A Multicenter, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF)Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric CancerStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Study of Bortezomib, Pomalidomide, Dexamethasone in Patients With Systemic AL AmyloidosisStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Search to Advance Limited Use of Opioids Pilot: Optimization of Non-Opioid Therapy With a SteroidStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of TherapyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2023-11-08
Clinical trial
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for Neonatal Acute Respiratory Distress SyndromeStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2025-05-18
Clinical trial
Enhanced Pain Control After Reduction Mammaplasty With Bupivicaine and Dexamethasone Regional Block: a Double-blind Randomized Controlled TrialStatus: Completed, Estimated PCD: 2020-11-07
Clinical trial
Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Ovarian Contribution to Androgen Production in Adolescent GirlsStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose TherapyStatus: Active (not recruiting), Estimated PCD: 2026-10-01
Clinical trial
A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma PatientsStatus: Active (not recruiting), Estimated PCD: 2027-12-31
Clinical trial
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for MaintenanceStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase I/II Study to Assess the Safety and Tolerability of the Combination of Oral ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2028-06-05
Clinical trial
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic AcidStatus: Active (not recruiting), Estimated PCD: 2020-10-31
Clinical trial
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic LymphohistiocytosisStatus: Completed, Estimated PCD: 2023-01-24
Clinical trial
Transforaminal Epidural Injection in Acute SciaticaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple MyelomaStatus: Completed, Estimated PCD: 2018-10-26
Clinical trial
Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Particulate Versus Non-Particulate Corticosteroid in Sacroiliac Joint Injection: A Randomized Prospective StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 PneumoniaStatus: Completed, Estimated PCD: 2021-02-26
Clinical trial
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic CholangiocarcinomaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization - Randomized Controlled Trial.Status: Not yet recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Dexamethasone, Olanzapine, Flow-targeted Versus Pressure-targeted Hemodynamic Management, and Low Tidal Volume Ventilation in Patients Undergoing On-pump Cardiac Surgery - a Multifactorial Design Randomized TrialStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Effect of Different Intraligamentary Injections on the Post-endodontic Pain in Patients With Symptomatic Irreversible PulpitisStatus: Recruiting, Estimated PCD: 2024-03-03
Clinical trial
Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand SurgeryStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
The Effect of Perioperative DEXamethasone on Postoperative Complications After PANcreaticoduodenectomyStatus: Completed, Estimated PCD: 2023-09-14
Clinical trial
The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy: A Randomised Double-blind, Placebo-controlled TrialStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Phase I Trial of Ribociclib in Combination With Everolimus and Dexamethasone in Children and Young Adults With Relapsed Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-03-04
Clinical trial
Dexamethasone and Postoperative Bleeding Following Tonsillectomy in Children: Double-blind, Randomized, Placebo Control, Multi-centre, International, Pragmatic, Non-inferiority TrialStatus: Terminated, Estimated PCD: 2023-03-30
Clinical trial
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance StrategyStatus: Completed, Estimated PCD: 2024-03-28
Clinical trial
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and EpendymomaStatus: Active (not recruiting), Estimated PCD: 2029-10-30
Clinical trial
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2024-02-01
Clinical trial
The Effect of Dexamethasone on Symptoms in Patients With Advanced CancerStatus: Active (not recruiting), Estimated PCD: 2021-02-28
Clinical trial
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Impact of Single Dose Perioperative Steroids on Dysphagia Following Anterior Cervical Spine Surgery: A Randomized, Prospective, Double-Blind StudyStatus: Active (not recruiting), Estimated PCD: 2023-07-30
Clinical trial
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen PlanusStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and DexamethasoneStatus: Recruiting, Estimated PCD: 2032-01-01
Clinical trial
Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip ArthroplastyStatus: Recruiting, Estimated PCD: 2025-03-30
Clinical trial
A Randomized Controlled Trial of Ultrasound Guided Knee Genicular Nerve Block and Anterior Femoral Cutaneous Nerve Block for Primary Total Knee ArthroplastyStatus: Recruiting, Estimated PCD: 2025-05-22
Clinical trial
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)Status: Not yet recruiting, Estimated PCD: 2028-12-25
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)Status: Recruiting, Estimated PCD: 2027-11-20
Clinical trial
Multicenter, Randomized, Double-blind, Parallel-group Study of Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's DiseaseStatus: Terminated, Estimated PCD: 2011-12-30
Clinical trial
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) StatusStatus: Withdrawn, Estimated PCD: 2020-05-28
Clinical trial
Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Randomised Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Pediatric Emergency DepartmentStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Isolated Adductor Canal Block vs Adductor Canal Block With IPACK in ACL Reconstruction: A Randomized, Prospective TrialStatus: , Estimated PCD: 2024-09-30
Clinical trial
A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2021-08-04
Clinical trial
A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseStatus: Terminated, Estimated PCD: 2022-12-06
Clinical trial
Carfilzomib - Lenalidmide - Dexamethasone (KRd) Versus Lenalidomi - Dexamethasone (Rd) in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation: a Randomized Phas III TrialStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Clinical Trial to Assess Whether Dexamethasone Addition to Standard Protocols for Non-Traumatic Rhabdomyolysis of Unknown or Genetic Etiologies Improves Patient OutcomesStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase III Randomized Control Trial Investigating Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients With Gynecologic Malignancies Receiving Every 3-week Carboplatin and Paclitaxel ChemotherapyStatus: Terminated, Estimated PCD: 2024-01-03
Clinical trial
Efficacy and Safety of Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Elderly or Unfit Patients With Ph-negative B-cell Acute Lymphocytic Leukemia: A Prospective, Single-arm Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
The Combination of Teriflunomide and High-dose Dexamethasone vs High-dose Dexamethasone Alone as First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia (ITP): A Prospective, Multicenter, Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-12
Clinical trial
A Randomized Controlled Trial Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia as Part of a Multimodal Antiemetic Strategy for Enhanced Recovery After Cesarean DeliveryStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell LeukemiaStatus: Completed, Estimated PCD: 2020-10-30
Clinical trial
Phase II Trial for Newly Diagnosed Low-risk Multiple Myeloma Patients Comparing 6 Cycles of Isatuximab With Lenalidomide/Bortezomib/Dexamethasone (I-VRD) Compared to 3 Cycles of I-VRD Followed by One Cycle of High-dose Therapy and Both Arms Followed by Maintenance Therapy With I-R.Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in the Treatment of Adult Newly Diagnosed Early Precursor T-cell Acute Lymphoblastic Leukemia (ETP-ALL)Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
High-dose Dexamethasone Plus Hetrombopag Versus High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia (ITP):A Prospective Multicenter Randomized TrialStatus: Recruiting, Estimated PCD: 2024-07-10
Clinical trial
The Effect of Preoperative Dexamethasone on Postimplantation Syndrome After Endovascular Aneurysm Repair - Protocol for a Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-05-31
Clinical trial
The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD - Multicentre Phase II Clinical Study - PLRG-HL1Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - the INSTAR StudyStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Rescue Quadratus Lumborum Blocks for Post-cesarean PainStatus: Withdrawn, Estimated PCD: 2022-06-30
Clinical trial
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma PatientsStatus: Completed, Estimated PCD: 2024-03-18
Clinical trial
Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Dexamethasone vs. Dexmedetomidine for Erector Spine Plane Block in Pain Management After Pediatric Idiopathic Scoliosis Surgery.Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
The Efficacy of Steroid-Sparing Anti-Emetic Therapy in Patients Treated With High or Moderate Emetogenic Chemotherapy; Single Center Non-Inferiority Open Label Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Effect of Perineural Dexamethasone on the Duration of Supraclavicular Brachial Plexus Block for Anesthesia After Pediatric Hand/Wrist SurgeryStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as Pre Transplant INDUCTION and Post Transplant Consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as Pre Transplant INDUCTION and Post Transplant Consolidation or Continuous Treatment With CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 Cycles) Without Transplant, All Followed by MAINTENANCE With LENALIDOMIDE (R) Versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANTStatus: Active (not recruiting), Estimated PCD: 2016-10-01
Clinical trial
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-12-28
Clinical trial
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic LymphomaStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple MyelomaStatus: Completed, Estimated PCD: 2021-05-05
Clinical trial
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic LeukemiaStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
The Effect of Intravenous Non-steroidal Anti-inflammatory Drugs and Intravenous Corticosteroids on the Likelihood of Dysphagia and Dysphonia Following Anterior Cervical Discectomy and FusionStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaStatus: Completed, Estimated PCD: 2018-11-01
Clinical trial
Efficacy and Safety of Local Glucocorticoids for the Treatment of Radiation-Induced Intestinal Injury: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin in Adults Receiving Axicabtagene Ciloleucel (Axi-Cel) TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-11-03
Clinical trial
FeAsiBility of a Treatment Free Interval in Newly Diagnosed mUltiple myeLOma Patients Treated With DaratumUmab-Lenalidomide-DexamethaSone- the FABULOUS Study. A Nationwide Open-label Randomized Phase III Clinical Trial Comparing Daratumumab-lenalidomide-dexamethasone Continuously Versus Including a Treatment Free IntervalStatus: Not yet recruiting, Estimated PCD: 2031-01-01
Clinical trial
A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)Status: Recruiting, Estimated PCD: 2025-12-25
Clinical trial
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaStatus: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Antenatal Dexamethasone for Late Preterm Deliveries: a Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-03-28
Clinical trial
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)Status: Active (not recruiting), Estimated PCD: 2022-04-29
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADDStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Status: Completed, Estimated PCD: 2021-06-01
Clinical trial
A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2012-04-01
Clinical trial
A Single-arm Prospective Study of the Treatment in High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsStatus: Recruiting, Estimated PCD: 2028-07-31
Clinical trial
Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis: a Non-inferiority Randomized Controlled Trial (Dexa-P)Status: Terminated, Estimated PCD: 2023-07-17
Clinical trial
The Danish Out-of-Hospital Cardiac Arrest Study - a Randomized, Placebo-controlled, Double-blind, Multi Center TrialStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)Status: Recruiting, Estimated PCD: 2026-03-26
Clinical trial
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation (JCM022)Status: Active (not recruiting), Estimated PCD: 2024-08-27
Clinical trial
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in AdultsStatus: Active (not recruiting), Estimated PCD: 2023-06-23
Clinical trial
Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean DeliveryStatus: Withdrawn, Estimated PCD: 2022-06-15
Clinical trial
Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery: A Randomized Controlled TrialStatus: Completed, Estimated PCD: 2022-06-18
Clinical trial
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2023-11-08
Clinical trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-04-02
Clinical trial
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic LeukemiaStatus: Terminated, Estimated PCD: 2020-04-02
Clinical trial
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-04-10
Clinical trial
An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-12-15
Clinical trial
Randomized Controlled Trial on Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone On Postoperative Complications Following Surgical Extraction Of Mandibular Third Molar.Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
Frontline Ruxolitinib With De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 StudyStatus: Not yet recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II ProtocolStatus: Active (not recruiting), Estimated PCD: 2025-05-22
Clinical trial
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase GenotypeStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Assessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Comparison to Topical Prednisolone Acetate Following Bilateral Small Incision Lenticule Extraction (SMILE)Status: Completed, Estimated PCD: 2021-06-21
Clinical trial
PD1 Blockade and Oncolytic Virus in Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2022-10-10
Clinical trial
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2021-12-20
Clinical trial
Dexamethasone as a Novel Treatment for Obstructive Sleep Apnea in ChildrenStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
A Phase Ib/II Clinical Trial of Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase II Study of Selinexor In Addition to Lenalidomide for Consolidation and Maintenance Treatment After Autologous Hematopoietic Cell Transplant in Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Periarticular Administration of Dexamethasone to Improve Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications in Patients Undergoing Hip Arthroplasty - A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2Status: Recruiting, Estimated PCD: 2026-02-04
Clinical trial
Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Effect of Systematic Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle SurgeryStatus: Completed, Estimated PCD: 2024-02-23
Clinical trial
Individualizing Corticosteroid Use in PneumoniaStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current TherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent MaintenanceStatus: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
A Multicenter Phase 1-DEC (Dose Expansion Cohort) Open-label Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaStatus: , Estimated PCD: 2024-08-01
Clinical trial
A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone MetastasesStatus: Completed, Estimated PCD: 2015-05-25
Clinical trial
Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal CancerStatus: Completed, Estimated PCD: 2023-07-31
Clinical trial
A Phase 1b/2 Study of Standard Doses of Bortezomib and Pembrolizumab ± Reovirus (Pelareorep) Combination Therapy in Patients With Relapsed Multiple Myeloma (AMBUSH Study)Status: Recruiting, Estimated PCD: 2025-10-07
Clinical trial
MCP Study, A Double-Blinded, Randomized Controlled Trial To Compare Multifidus Cervicis Plane Block (MCP) Vs. Sham Block, In Reducing Postoperative Pain And Opioid Consumption In Patients Undergoing Elective Primary Posterior Cervical Spine Fusion Surgery (CSFS)Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis: A Double-Blind Prospective Randomized Clinical TrialStatus: Terminated, Estimated PCD: 2022-05-19
Clinical trial
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
FOLFOX Via Hepatic Artery Infusion Chemotherapy (HAI) Plus Systemic Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical StudyStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS TrialStatus: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF : Double Blinded, Randomized Control TrialStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-11-30
Clinical trial
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-01-30
Clinical trial
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Multimodal Nonopioid Pain Protocol Following Shoulder Arthroplasty SurgeryStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2031-05-01
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase1 Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)Status: Active (not recruiting), Estimated PCD: 2016-06-01
Clinical trial
Comparison of the Analgesic Efficacy of a Single Shot Interscalene Block With Liposomal Bupivacaine to Bupivacaine With Dexamethasone as an adjuvant-a Randomized Controlled TrialStatus: Completed, Estimated PCD: 2022-04-05
Clinical trial
Dexamethasone in Total Knee Arthroplasty: What Dose Should we be Giving Patients IntraoperativelyStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response - A Randomized Double-blind Placebo-controlled TrialStatus: Active (not recruiting), Estimated PCD: 2024-03-22
Clinical trial
The Efficacy of Botulinum Toxin to the Flexor Digitorum Brevis Versus Corticosteroid to the Plantar Fascia for the Treatment of Refractory Plantar Fasciitis: A Randomized-Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2024-04-26
Clinical trial
Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19Status: Completed, Estimated PCD: 2023-07-17
Clinical trial
Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDiseaseStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
ALL Adult Consortium Trial: Adult ALL TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Ultrasound-guided Intermediate Cervical Plexus Block in Patients Undergoing ThyroidectomyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleStatus: Recruiting, Estimated PCD: 2033-06-01
Clinical trial
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye SyndromeStatus: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency AblationStatus: Terminated, Estimated PCD: 2022-10-14
Clinical trial
Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
The Impact of Perioperative Steroid Dosing on the Acute Phase Response in Adolescent Idiopathic ScoliosisStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)Status: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
Effect of Preoperative Administration of Dexamethasone Versus Methylprednisolone in Surgical Extraction of Retained Lower Third MolarsStatus: Completed, Estimated PCD: 2023-07-01
Clinical trial
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyStatus: Completed, Estimated PCD: 2024-05-08
Clinical trial
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of VenetoclaxStatus: Not yet recruiting, Estimated PCD: 2027-12-21
Clinical trial
Verification of the Efficacy / Safety of the Intratympanic Drug Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)Status: Recruiting, Estimated PCD: 2023-04-18
Clinical trial
Comparison of Topical Hydrocortisone Versus Dexamethasone Treatment for Inflammatory Secretions of the Conjonctiva in Patients With Ocular ProsthesesStatus: Recruiting, Estimated PCD: 2025-05-25
Clinical trial
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory MyelomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission MaintenanceStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-11-11
Clinical trial
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-11-07
Clinical trial
Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry EyeStatus: Completed, Estimated PCD: 2019-12-01
Clinical trial
Intraoperative Electrical Stimulation of the Acupoint P6 to Prevent Post-Operative Nausea and Vomiting in Women Undergoing Breast Cancer SurgeryStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Comparative Study Between Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Long- Term Pain ReliefStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Effects of Peri-Operative Glucosteroid Administration on Outcomes Following Distal Radius FractureStatus: Terminated, Estimated PCD: 2023-05-02
Clinical trial
Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving CarboplatinStatus: Terminated, Estimated PCD: 2021-02-11
Clinical trial
A Randomized Trial of Postoperative Steroid Use Following Posterior Spinal Fusion in 100-subject Adolescent Idiopathic Scoliosis (AIS) and Neuromuscular Scoliosis (NMS)Status: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the Treatment of Lumbosacral Radicular Pain Due to Spinal Stenosis: Improving Safety and Outcomes in the Treatment of Pain and Disability Related to Spinal Stenosis.Status: Recruiting, Estimated PCD: 2025-01-20
Clinical trial
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
Multi-level Molecular Profiling of Stress Exposure Under Standardized Food Intake: A Clinical StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment LinesStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African CountriesStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Phase 2 Study Assessing Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone in Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple MyelomaStatus: Completed, Estimated PCD: 2021-07-27
Clinical trial
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell LymphomaStatus: Completed, Estimated PCD: 2012-10-01
Clinical trial
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior TherapiesStatus: Completed, Estimated PCD: 2019-06-19
Clinical trial
A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II TrialStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of Early Administration of Dexamethasone in High-risk SepsisStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Effects of Physical Activity Plus Short Course of Dexamethasone for Cancer-Related Fatigue in Advanced CancerStatus: Active (not recruiting), Estimated PCD: 2019-03-28
Clinical trial
Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma PatientsStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL PatientsStatus: Active (not recruiting), Estimated PCD: 2022-08-01
Clinical trial
Ultrasound-guided Quadratus Lumborum Block Using Bupivacaine Versus Bupivacaine - Dexamethasone as Postoperative Analgesia in Laparoscopic CholecystectomyStatus: Completed, Estimated PCD: 2023-08-01
Clinical trial
Does Low Dose of Dexamethasone Enhance Analgesic Quality of Caudal Analgesia in Children Undergoing Orchiopexy?Status: Completed, Estimated PCD: 2023-08-29
Clinical trial
Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 YearsStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time Optical Coherence Tomography During OperationStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
TREAT-SC: A Randomised, Double-Blinded, Placebo-Controlled Trial of Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in ChildrenStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
AMN006 - Phase 2 Study of Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma PatientsStatus: Active (not recruiting), Estimated PCD: 2021-09-30
Clinical trial
Analgesia After Total Knee Arthroplasty: Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI). A Double-Blinded Randomized Controlled TrialStatus: Completed, Estimated PCD: 2018-05-31
Clinical trial
Does Nerve Block Plus Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hours Better Than Nerve Block Alone?Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaStatus: Completed, Estimated PCD: 2016-07-06
Clinical trial
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem TransplantsStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive CytologyStatus: Recruiting, Estimated PCD: 2028-10-31
Clinical trial
Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy- a Double-blinded Placebo Controlled RCTStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Clinical trial
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) LymphomaStatus: Terminated, Estimated PCD: 2015-07-01
Clinical trial
The Effectiveness of Preemptive Nebulized Dexamethasone in Reducing Post- Operative Sore Throat Following the Use of AMBU® AURAGAINTM Device: A Double Blind, Randomised Clinical TrialStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
A Randomized Controlled Trial to Evaluate a Novel Analgesia Technique for ACL Reconstruction: Adductor Canal Block With an IPACK Versus Adductor Canal BlockStatus: Active (not recruiting), Estimated PCD: 2021-03-16
Clinical trial
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First RelapseStatus: , Estimated PCD: 2028-06-30
Clinical trial
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenStatus: Active (not recruiting), Estimated PCD: 2022-07-24
Clinical trial
Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUSStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-04-19
Clinical trial
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Prospective Randomized Comparative Trial for Combination Dexamethasone Implant With PRN Anti-VEGF Therapy to Anti-VEGF Therapy Alone in Treatment Resistant DME: Informing the Role for Imaging BiomarkersStatus: Completed, Estimated PCD: 2024-01-31
Clinical trial
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell LymphomaStatus: Recruiting, Estimated PCD: 2034-01-31
Clinical trial
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)Status: Active (not recruiting), Estimated PCD: 2023-09-26
Clinical trial
Effect of Adding Dexamethasone to Bupivacaine 0.25% in Superficial Cervical Plexus Block on Surgical Field Visibility During Tympanomastoid Surgery in Adults, A Randomized Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
Randomized Controlled Trial Assessing the Effect of Intraoperative Dexamethasone in the Management of Postoperative Analgesia and Stiffness After Distal Radius FixationStatus: Completed, Estimated PCD: 2023-07-01
Clinical trial
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene RearrangementStatus: Active (not recruiting), Estimated PCD: 2020-09-30
Clinical trial
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2021-05-05
Clinical trial
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
An Open Label, Single Arm, Multi-Center Exploratory Study to Evaluate the Efficacy and Safety of SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease.Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
The Bronchiolitis in Hospitalized Infants (BroncHI) Study: A Feasibility Trial Aimed to Identify and Treat Hospitalized Infants With Bronchiolitis Most at Risk for Recurrent Wheezing and AsthmaStatus: Withdrawn, Estimated PCD: 2025-03-09
Clinical trial
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Randomized, Controlled Trial of Post-operative Steroids and Pain Control After TonsillectomyStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell LymphomaStatus: Completed, Estimated PCD: 2018-04-26
Clinical trial
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLHStatus: Recruiting, Estimated PCD: 2026-04-20
Clinical trial
Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries: a Double Blind, Placebo-controlled StudyStatus: Completed, Estimated PCD: 2018-08-31
Clinical trial
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma SubjectsStatus: Active (not recruiting), Estimated PCD: 2021-09-01
Clinical trial
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Low-dose Baricitinib Plus High-dose Dexamethasone as First-line Treatment for Patients With Newly Diagnosed Immune Thrombocytopenia: a Multicenter, Open-label, Randomized, Controlled, Phase 2 TrialStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)Status: Recruiting, Estimated PCD: 2026-09-15
Clinical trial
Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS: a Pilot Study of a Prospective, Multicenter, Double-blind, Double-mock Randomized Controlled Clinical StudyStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I De-Escalation Study of Dexamethasone With Azeliragon for Management of Post-Resection Cerebral Edema in Patients With GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2024-11-29
Clinical trial
Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AIStatus: Recruiting, Estimated PCD: 2025-09-10
Clinical trial
A Prospective, Randomized, Active-Comparator, Open-Label, Non-Inferiority Study of the Efficacy of Continuous Nerve Block vs Single Block Plus Intravenous Lidocaine for Postoperative Pain.Status: Terminated, Estimated PCD: 2022-08-18
Clinical trial
Conventional Prophylactic Regimen of Oral Dexamethasone Versus Short-course Intravenous Dexamethasone in Preventing Paclitaxel-related Hypersensitivity Reactions in Breast and Gynecologic Oncology PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTSStatus: Completed, Estimated PCD: 2015-07-01
Clinical trial
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaStatus: Completed, Estimated PCD: 2018-12-12
Clinical trial
Oral Dexamethasone as an Adjunct to a Brachial Plexus Block in Patients Undergoing Orthopaedic Surgery of the Forearm and Hand. A Randomised, Blinded, Placebo-controlled, Parallel, Triple-arm Clinical Trial.Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-01-31
Clinical trial
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic EffectStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes MellitusStatus: Withdrawn, Estimated PCD: 2021-12-01
Clinical trial
Effect of Intravenous Dexamethasone on the Duration of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery, Randomized Controlled TrialStatus: Completed, Estimated PCD: 2023-04-01
Clinical trial
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple MyelomaStatus: Completed, Estimated PCD: 2021-04-13
Clinical trial
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus: Completed, Estimated PCD: 2015-06-01
Clinical trial
BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Perioperative IV Steroid Administration Lowers Post-operative Pain Levels and Opioid Use in Pediatric Patients After Posterior Spinal Fusion and Instrumentation for Spine Deformity.Status: , Estimated PCD: 2025-01-01
Clinical trial
Dexamethasone as Adjuvant to Ropivacaine in Wound Infiltration for Postoperative Analgesia Following Spinal Surgery: A Randomized, Double-Blinded, Controlled TrialStatus: Completed, Estimated PCD: 2023-02-04
Clinical trial
Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-InStatus: Recruiting, Estimated PCD: 2024-10-21
Clinical trial
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection: A Randomized Controlled Double-Blind StudyStatus: Terminated, Estimated PCD: 2022-08-12
Clinical trial
A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment With an Intracanalicular Dexamethasone (0.4mg) Ophthalmic Insert in the Operating Room Following Cataract Surgery/Intraocular Lens Implant (IOL) Compared to Insertion 1-day Post-op - The SITE StudyStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate ConsortiumStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Hormonal Mechanisms of Sleep Restriction - Axis StudyStatus: Active (not recruiting), Estimated PCD: 2020-10-30
Clinical trial
Multicenter Phase II Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone in Elderly Unfit Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
The Effect of Preoperative Intravenous Dexamethasone on Postoperative Rebound Pain and Sleep Quality in Patients Receiving Ultrasonography-Guided Ilioinguinal and Iliohypogastric Nerve Block for Inguinal Hernia RepairStatus: Completed, Estimated PCD: 2023-04-15
Clinical trial
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled TrialStatus: Completed, Estimated PCD: 2021-11-08
Clinical trial
DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular LensesStatus: Completed, Estimated PCD: 2022-12-12
Clinical trial
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Bortezomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty. The RECIPE Randomized Clinical TrialStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersStatus: Withdrawn, Estimated PCD: 2023-09-18
Clinical trial
Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients: A Phase 2 Study With a Safety Run-inStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Combined Intravenous Dexamethasone and Dexmedetomidine as Adjuncts to Popliteal and Saphenous Nerve Blocks in Patients Undergoing Orthopaedic Surgery of the Foot and Ankle. A Randomised, Blinded, Placebo-controlled, Parallel Clinical TrialStatus: Completed, Estimated PCD: 2023-04-17
Clinical trial
A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Status: Recruiting, Estimated PCD: 2024-12-24
Clinical trial
A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTSStatus: Active (not recruiting), Estimated PCD: 2013-11-01
Clinical trial
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)Status: Active (not recruiting), Estimated PCD: 2020-02-01
Clinical trial
Efficacy of Dengue Infection With Warning Signs Treated With DexamethasoneStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)Status: Terminated, Estimated PCD: 2021-01-20
Clinical trial
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-05-01
Clinical trial
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic LeukaemiaStatus: Terminated, Estimated PCD: 2023-05-03
Clinical trial
The Outcomes and Safety of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients With Hemorrhage ComorbidityStatus: Recruiting, Estimated PCD: 2024-01-18
Clinical trial
Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhageStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in AdultsStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Manipulation Under Anesthesia (MUA) to Treat Postoperative Stiffness After Total Knee Arthroplasty: A Multicenter Randomized Clinical TrialStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal InsufficiencyStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Transforaminal Epidural Platelet Rich Plasma Versus Epidural Steroid Injection for Lumbosacral Radicular Pain: a Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Clinical trial
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to RituximabStatus: Completed, Estimated PCD: 2012-11-14
Clinical trial
Preemptive Use of Etoricoxib and Dexamethasone: Effect on Early Bone Healing, Inflammatory Response, and Postoperative Parameters After Impacted Lower Third Molar SurgeryStatus: Completed, Estimated PCD: 2022-12-26
Clinical trial
DEXRAR: DEXamethasone in Revision ARthroplasty: A Randomised, Blinded, 2-group Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.Status: Recruiting, Estimated PCD: 2023-04-18
Clinical trial
The Effect of Intercostal Nerve Block With Dexamethasone and Ropivacaine on Rebound Pain After Thoracoscopic Surgery: a Randomized, Double-blind, Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2025-05-05
Clinical trial
Traditional Chinese Medicine or Low-dose Dexamethasone in Symptomatic Patients With Post-COVID-19 Parenchymal Lung Abnormalities: a Randomized Controlled Trial Three Arm, Parallel Group, Single Blind, Randomized Controlled Trial.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants With Retinopathy of Prematurity- a Feasibility StudyStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Oral Dexamethasone at Night to Prevent Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Protocol for Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Perineural Dexmedetomidine vs Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle SurgeryStatus: Not yet recruiting, Estimated PCD: 2025-03-31
Clinical trial
Adrenal Venous Sampling Under 1 mg Overnight Dexamethasone Suppression Test to Determine Subtype in Primary Aldosteronism，a Single Center, Randomized, Double Blended, Placebo Controlled Clinical TrailStatus: Completed, Estimated PCD: 2022-10-30
Clinical trial
Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients (COSMIC): A Pilot Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Adjuncts for Adductor Block: Dexamethasone,Dexmedetomidine, or Combination to Reduce Pain. A Randomized Controlled Comparison of the Analgesic Effects Following ACL RepairStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
The Effectiveness of Combined U.S. Guided Erector Spinae and Pecto-intercostal Fascial Plane Blocks Versus U.S.Guided Thoracic Paravertebral Block in Controlling Perioperative Pain in Modified Radical Mastectomy, a Blinded Randomized Controlled TrialStatus: Completed, Estimated PCD: 2023-03-09
Clinical trial
Randomised Evaluation of COVID-19 TherapyStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Dexamethasone Use for the Treatment of Non-RSV BronchiolitisStatus: Terminated, Estimated PCD: 2022-12-31
Clinical trial
The Efficacy of Orally Administered Dexamethasone in the Management of Symptomatic Irreversible Pulpitis Without Performing Pulpotomy : : A Single-arm Open Clinical TrialStatus: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
Optimized Immunosuppression for Corneal Transplantation: A Multi-center Randomized Controlled Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
Venetoclax Combined With Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis Patients With Translocation (11;14): A Multicenter Phase 2 StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Using a Single Dose of Dexamethasone at 0.6mg/kg of Body Weight Versus 0.15 mg/kg of Body Weight for the Treatment of Croup: an Internal Vanguard Randomized Controlled Non-Inferiority Trial.Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple MyelomaStatus: , Estimated PCD: 2025-11-01
Clinical trial
Randomized Open Investigation Determining Steroid Dose (ROIDS-Dose)Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 PatientsStatus: Completed, Estimated PCD: 2021-08-27
Clinical trial
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
The Efficacy and Safety of Hydroxychloroquine Plus Dexamethasone in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Trans-foraminal Lumbar Epidural Injection of Dexmedetomidine Against Magnesium Sulfate When Combined With Dexamethasone in Uni-lateral Lower Limb Radicular Pain. Multi-centeric Comparative StudyStatus: Completed, Estimated PCD: 2023-02-10
Clinical trial
The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee ArthroplastyStatus: Recruiting, Estimated PCD: 2025-02-01
Document
DailyMed Label: HemadyOrganization
Acrotech Biopharma LLCOrganization
Edenbridge Pharmaceuticals LLC.Document
DailyMed Label: BaycadronOrganization
Wockhardt USA, LLC